Skip to Primary Navigation

CMS and FDA unveil a fast track for Medicare access to breakthrough devices

Photo: RonBailey/Getty Images

Initial reactions to the new regulatory pathway from medtech industry groups ranged from mostly positive to cautious.

The Centers for Medicare & Medicaid Services (CMS) and the US Food and Drug Administration (FDA) have announced a new regulatory framework designed to accelerate Medicare coverage for certain FDA‑designated Class II and Class III breakthrough devices.

The goal of the new Regulatory Alignment for Predictable and Immediate Device

Get full access, free for a month

Start your 28-day free trial to continue reading and access
all content on GRIP – no payment details required.

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience